European Commission Grants Approval for Mavenclad (Cladribine Tablets)
First oral short-course treatment for highly active relapsing multiple sclerosis (RMS)[1] now approved in Europe
MAVENCLAD® has shown sustained clinical efficacy for up to 4 years with a maximum of 20 days of oral treatment over 2 years
Marketing... Biopharmaceuticals, Neurology, Regulatory Merck, MAVENCLAD, Cladribine, multiple sclerosis
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news